BioLife secures CAR T-cell therapy development deal

By The Science Advisory Board staff writers

October 4, 2021 -- BioLife Solutions has secured a deal with an undisclosed global pharmaceutical company to support that firm's regulatory and commercial launch of a new CAR T-cell therapy.

Under the terms of the deal, the pharmaceutical firm will use BioLife's CryoStor media, the evo cold-chain management platform, and SciSafe storage with Stirling UltraCold freezers.

The company's CryoStore freeze media is currently being used by Kite/Gilead, Bluebird Bio, and Bristol Myers Squibb, it said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.